FundingHealthcare & Life Sciences
4baseCare raises ₹90 crore in Series B
By Abha Lohia · Editor ·
4baseCare: revenue and funding and every story →
series-bFounded 2018
- 4baseCare is a precision oncology company that integrates genomic testing with clinical data
- It raised ₹90 crore in a Series B round co-led by Ashish Kacholia and Lashit Sanghvi
- The funds will expand its genomics lab network and develop AI-based clinical decision tools
What happened
- 4baseCare announced the first close of its Series B funding round.
- The company raised ₹90 crore (approximately $9.8 million).
- The round was co-led by Ashish Kacholia and Lashit Sanghvi.
- Existing investor Yali Capital also participated in the round.
- The company plans to use the funds to expand its hospital-linked genomics lab network across India, the Middle East, Southeast Asia, Latin America, and Central Asia.
- It will also accelerate development of AI-based clinical decision support solutions, including OncoTwin Insights.
- OncoTwin Insights helps oncologists derive treatment insights from clinico-genomic and outcomes-linked datasets.
- The company's OncoTwin was selected for the MSK iHub programme of Memorial Sloan Kettering Cancer Centre in New York.
Why it matters
- The healthtech market is projected to grow at 39% CAGR from 2025 and exceed $37 billion by 2030.
- About $700 million was raised by healthtech startups in 2025.
- This round comes after a gap of two years since the Series A in 2024.
- The company also received a grant from the Karnataka government in 2024.
The business
- 4baseCare is a precision oncology company that builds population-relevant clinico-genomic intelligence.
- It integrates genomic testing with real-world clinical and outcomes data to provide actionable insights.
- The company works with hospitals to offer genomics-led cancer diagnostics in clinical settings.
- Its product OncoTwin Insights helps oncologists derive treatment insights from clinico-genomic and outcomes-linked datasets.
- The company was selected for the MSK iHub programme of Memorial Sloan Kettering Cancer Centre.
The founders
HG
Hitesh Goswami
CEO- Hitesh Goswami founded 4baseCare.
- He serves as the CEO of the company.
Who put in money
- Ashish Kacholia lead
- Lashit Sanghvi lead
- Yali Capital existing — Existing investor that also led the Series A round.
In numbers
₹90 croreSeries B amount · 2026
$9.8 millionSeries B amount in USD · 2026
₹50 croreSeries A amount · 2024
₹8.3 croreInfosys investment in Series A · 2024
What happens next
- Expand hospital-linked genomics lab network across India, Middle East, Southeast Asia, Latin America, and Central Asia.
- Accelerate development and deployment of AI-based clinical decision support solutions, including OncoTwin Insights.
Earlier rounds
- 2024 · Series A · ₹50 crore · led by Yali Capital
Up against
Everhope OncologyMOC Cancer Care & Research CentreErlySignOnCareOneCell Diagnostics
Words to know
- precision oncology
- A medical approach that uses genetic information about a patient's cancer to tailor treatment.
- genomic testing
- Laboratory tests that look at a person's DNA to find changes that may cause or increase the risk of disease.
- clinico-genomic
- Combining clinical data (like symptoms and test results) with genomic data (DNA information).
- Series B
- A later-stage funding round for startups that have already proven their business model and need capital to scale.
The numbers around it
4baseCare has 2 funding rounds in StopDown's archive, Rs 128 Cr raised in all.
| When | Round | Amount | Led by |
|---|---|---|---|
| 11 June 2026 | Series B | Rs 128 Cr | growX Ventures |
Healthcare & Life Sciences in January 2026: 12 rounds with a disclosed amount, $99.0 million in all; the biggest was Sukino ($31M). Every sector this year →
Other articles talking about it
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
- Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on 4baseCare → · All startup news on 27 January 2026 →
Is this 4baseCare? Get your “Featured on StopDown” badge →